drugset / Trial / NCT02231710
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-09
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimiducid | Other / unclassified | — | — |
| Subject | rivogenlecleucel | Cell therapy | 3e+06 cells/kg | — |
| Subject | rivogenlecleucel | Cell therapy | 1e+07 cells/kg | — |